Pharming Group: Small Dutch Company With Strong Revenues
Source: SeekingAlpha
2025-04-01 08:45:40 ET
Summary
- Pharming Group, a Dutch biotech firm, excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow despite low US trading volume.
- RUCONEST and JOENJA drive revenue, with RUCONEST contributing $252.2M and JOENJA surging 147% to $45M in its first full year.
- Acquired KL1333, a promising late-stage molecule for mitochondrial diseases, enhancing their pipeline and expanding market potential.
- Despite low US trading volume, Pharming Group's robust financials and growth prospects make it a compelling investment for those with access to Euronext.
...
Read the full article on Seeking Alpha
For further details see:
Pharming Group: Small Dutch Company With Strong Revenues
Pharming Group N.V.
NASDAQ: PHAR
PHAR Trading
4.35% G/L:
$15.84 Last:
4,011 Volume:
$15.44 Open:
PHAR Latest News
PHAR Stock Data
$1,106,258,522
65,794,170
N/A
5
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
